Regulation of Beclin 1-Mediated Autophagy by Oncogenic Tyrosine Kinases

Silvia Vega-Rubín-de-Celis 1,*, Lisa Kinch 2 and Samuel Peña-Llopis 3

1 Institute for Cell Biology (Cancer Research), University Hospital Essen, 45147 Essen, Germany
2 Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; lkinch@chop.swmed.edu
3 Translational Genomics in Solid Tumors, German Cancer Consortium (DKTK) and German Cancer Research Center, University Hospital Essen, 45147 Essen, Germany; Samuel.Pena-Llopis@dkfz-heidelberg.de

* Correspondence: silvia.vegarubindecelis@gmail.com or silvia.vegarubindecelis@uk-essen.de

Received: 30 October 2020; Accepted: 1 December 2020; Published: 3 December 2020

Abstract: Beclin 1 is a major regulator of autophagy, and it is a core component of the class III PI3K complexes. Beclin 1 is a highly conserved protein and its function is regulated in a number of ways, including post-translational modifications. Several studies indicate that receptor and non-receptor tyrosine kinases regulate autophagy activity in cancer, and some suggest the importance of Beclin 1 tyrosine phosphorylation in this process. Here we summarize the current knowledge of the mechanism whereby some oncogenic tyrosine kinases regulate autophagy through Beclin 1.

Keywords: Beclin 1; autophagy; tyrosine kinases; cancer

1. Introduction

Macroautophagy, herein referred to as autophagy (self-eating), is an intracellular degradation pathway whereby cytosolic components are engulfed into double-membrane structures (autophagosomes) for their degradation into the lysosome. Through this pathway, the cell can generate energy by recycling cytoplasmic components, but it can also control cytoplasmic quality by degradation of damaged proteins and organelles, lipid droplets, or intracellular pathogens. Autophagy is an essential process involved in both physiological and pathological conditions, including protection against aging, infections, cancer and neurodegenerative, metabolic, inflammatory, and muscle diseases [1–6]. Beclin 1 is an essential autophagy protein, that is regulated through multiple post-translational modifications, including phosphorylation by oncogenic tyrosine kinases. Thus, the goal of this mini-review is to compile the data available regarding the autophagy regulation through Beclin 1 tyrosine phosphorylation in cancer.

2. The Role of Beclin 1 in Autophagy and Cancer

Beclin 1, the mammalian ortholog of the yeast Atg6/Vps30 is an evolutionary conserved protein that is essential for autophagy. Beclin 1 was discovered as a binding partner of Bcl-2 in a yeast-two hybrid screen [7], and it was shown that Bcl-2 and Bcl-XL inhibit autophagy through their binding with Beclin 1 [8].

Beclin 1 is part of two distinct mayor class III phosphatidylinositol 3-kinase (PI3KC3) complexes: PI3KC3-C1 (it is involved in autophagosome nucleation and it contains Beclin 1, VPS34, VPS15 and ATG14) and PI3KC3-C2 (it is implicated in endolysosomal and autophagolysosome nucleation and containing Beclin 1, VPS34, VPS15 and UVRAG). A third PI3KC3 has been described, in which Beclin 1 binds to VPS34, VPS15, UVRAG, and RUBICON to inhibit autophagic flux [9–11] (Figure 1).
Figure 1. Beclin 1 forms several class III phosphatidylinositol 3-kinase (PI3KC3) complexes that regulate some steps of autophagy and endocytic trafficking.

One of the major events regulating autophagy is the formation of the Bcl-2/Bcl-xL—Beclin 1 complex formation. Bcl-2 and Bcl-xL inhibit autophagy through its binding to the BH3 domain of Beclin 1, stabilizing Beclin 1 homodimerization, disrupting Beclin 1 interaction with other components of the PI3KC3 complex and inhibiting autophagy [7]. The interaction of Bcl-2/Bcl-xL with Beclin 1 is regulated through multiple phosphorylation events that lead to promoting or disrupting the complex formation, including: (1) starvation-induced JNK1 (c-Jun amino terminal kinase 1) phosphorylation of Bcl-2 at T69, S70, and S97, promoting the dissociation of Bcl-2-Beclin 1 and the subsequent autophagy activation [12]; (2) Beclin 1 phosphorylation at T119 within its BH3 domain by DAPK (death associated protein kinase) or ROCK1 (Rho kinase 1) [13,14] promoting its dissociation from Bcl-2 and autophagy induction; (3) starvation-induced Beclin 1 phosphorylation at S90 by the stress responsive kinases MK2 and MK3, disrupting its binding with Bcl-2 and inducing autophagy [15]; (4) Mst1 (mammalian Ste20-like kinase 1) phosphorylation of Beclin 1 at T108 (within its BH3 domain), promoting the interaction of Bcl-2 and Beclin 1 and therefore inhibiting autophagy [16].

Beclin 1 (BECN1) is not frequently mutated in cancer. Only 106 out of 45,151 patients (less than 0.1%) from all tumor types found at cBioPortal (www.cbioportal.org) show alterations, and around 0.5% mutations (215 out of 38,262 unique samples) were found in the COSMIC database (Catalog of Somatic Mutations; https://cancer.sanger.ac.uk/cosmic). Beclin 1 functions as a haploinsufficient tumor suppressor, and allelic loss of Beclin 1 is frequently found in sporadic breast, ovarian, and prostate cancers [17–20]. Beclin 1 loss is associated with poor patient survival and more aggressive cancers [21] and mouse models harboring a single Beclin 1 copy have elevated incidence of spontaneous malignancies, including lung carcinomas, lymphomas, hepatocellular carcinomas and breast carcinomas [22–24].

3. Oncogenic Tyrosine Kinases

Tyrosine kinases (TKs) are enzymes that phosphorylate substrates at tyrosine residues and play essential roles in signal transduction, cell growth, migration, proliferation, differentiation, and survival. TKs are divided into receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (NRTK).

3.1. Receptor Tyrosine Kinases

RTKs are transmembrane tyrosine kinases, they are classified in 20 different classes, and all of them share a common structure, having a highly glycosylated extracellular ligand binding domain, a single transmembrane domain, and an intracellular domain containing a tyrosine kinase domain and a carboxy-terminal tail [25]. Aberrant function of RTK lead to different diseases, including cancer. Under normal conditions, most RTK are activated by binding to their corresponding ligand through the extracellular domain, dimerization, and a conformational change resulting in trans-phosphorylation of each kinase and release of the cis-autoinhibition [26]. This phosphorylation and further activation recruit other molecules that activate downstream signaling pathways. Several mechanisms are...
involved into the aberrant activation of tyrosine kinases found in cancers, including gain-of-function mutations, increased RTK levels by overexpression or amplification, chromosomal rearrangements, kinase domain duplication, or autocrine activation [26,27]. Upon activation, RTK initiate a cascade of downstream signaling pathways, including the PI3K/Akt/mTOR pathway, MAPK, AMPK or the Ras/MEK/ERK pathway, and most of them are also implicated in autophagy regulation through different mechanisms [26].

3.2. Non-Receptor Tyrosine Kinases

NRTKs are cytosolic kinases with a quite variable structure subunit composition but that usually harbor a protein kinase domain and some protein–protein interaction domains, like Src Homology 2 (SH2), SH3 or PH (Pleckstrin homolog) domains, and are organized into 9 subfamilies [28]. NRTKs are involved in regulation of proliferation, cell growth, adhesion, migration, and apoptosis, and they also regulate signal transduction in the immune system [29]. Multiple oncogenic alterations have been described in NRTKs, including chromosomal rearrangements leading to fusion genes, typically associated with hematological malignancies [29].

4. Beclin 1 Regulation by Tyrosine Phosphorylation

Mammalian Beclin 1 function is regulated at different levels to modulate autophagy and other intracellular processes where Beclin 1 is involved, including vacuolar protein sorting or LC3-associated phagocytosis through the class III PI3Kinase complex. These multiple regulation levels include post-translational modifications (phosphorylation, ubiquitination, acetylation), changes in Beclin 1 subcellular localization (sequestration at the Golgi or at the cytoskeleton, or endosomal localization), or variations at the interactome.

Multiple Beclin 1 phosphorylation events have been reported that eventually modulate autophagy activity in mammals, either by induction or inhibition (reviewed in [30,31]), and multiple oncogenic kinases have also been involved in autophagy modulation through Beclin 1 phosphorylation [32]. Phosphorylation at Ser90 has been shown to activate autophagy through several kinases, including MK2/3 [15], DAPK3, [33], calcium-calmodulin-dependent protein kinase type II (CAMKII, [34]), AMP-activated protein kinase (AMPK, [35]), and also by the phosphatase PP2A [33]. Other activating phosphorylated residues in Beclin 1 include Ser93 and Thr388 (phosphorylated by AMPK, [36]), Ser30 (PGK1, [37]), and Thr119 (phosphorylated by DAPK [14] and ROCK1 [13]). Additional phosphorylation events in Beclin 1 were reported to inhibit autophagy in different ways, including (1) cytoskeletal sequestration of Beclin 1 through 14-3-3 binding upon AKT1 phosphorylation at residues Ser234 and Ser295 [38]; (2) Beclin 1 dimerization and modification of its binding partners upon phosphorylation at Tyr229, Tyr233 and Tyr352 by EGFR [39] or at Tyr233 by HER2 mutants [40] and FAK [41]; (3) Increased binding of Beclin 1 with Bcl-2 and decreased binding with Vps34 through Beclin 1 phosphorylation at Thr108 by Mst-1 [16].

Human Beclin 1 protein contains a total of 11 tyrosines: Y162 (flexible helix domain, FHD), Y229, Y233, Y256 (CCD domain) and Y328, 333, 338, 352, 394, 413, and 448 located within the C-terminal ECD-BARA domain (Figure 2). Some of them are highly conserved across species, from human to yeast, including Y162 (located at the FHD domain) and Y394 and Y448 (located within the BARA domain). In the structure of the yeast VPS34 complex II [42], the FHD helix interacts with a helix from the VPS38 (UVRAG) and a helix from the scaffolding ARM repeat of VPS15 (P13R4) (Figure 3). The Y162 sidechain points towards the intersection of these two helices, suggesting it may play a role in positioning the complex. The Y394 sidechain is exposed to solvent in the complex structure model, suggesting that phosphorylation would be allowed in the complex (Figure 3). So far, only a handful of these residues have been shown to be phosphorylated by tyrosine kinases, and they all have an effect on regulating autophagy.
A crystal structure of the yeast VPS34 complex II [42] includes VPS34 (PIK3C3), VPS15 (PIK3R4), VPS30 (BECN1), and VPS38 (ATG14 or UVRAG). This structure provides a model for Beclin 1 interaction with the human complex components and its activation of phosphatidylinositol-3-kinase (PI3K) that leads to autophagy. The central coiled coils (CCD) of Beclin 1 and ATG14 (or the structurally related UVRAG of complex II) form a parallel heterodimer, which positions the Beclin 1 ECD/BARA domain at the tip of one arm of a Y-shaped complex structure (Figure 3).

The Beclin 1/ATG14 heterodimeric CCD forms an elongated platform for its interaction with an intertwined VPS15/VPS34 kinase heterodimer. The interaction positions the active site of the VPS34 kinase at the tip of the other arm of the Y. The presence of the Beclin 1 CCD heterodimer increases PI3K activity on vesicles. Deletion of a BARA domain “aromatic finger”, which is thought to mediate interaction with the membrane, lowers this activity [42,43]. Thus, activation of PI3K by the Beclin 1 CCD heterodimer is thought to increase VPS34 PI3K activity by interacting directly with the membrane where substrate resides.

In the absence of ATG14, the Beclin 1 CCD alone forms metastable antiparallel homodimers that transition to heterodimeric CCD upon addition of ATG14 or UVRAG. This structure mimics the full-length protein, with the BARA domain contributing to the strength of the CCD interaction [46], suggesting that the CCD equilibrium is influenced by other Beclin 1 domains. Thus, phosphorylation of Beclin 1 could modulate the equilibrium between its inactive homodimeric CCD state and the active heterodimeric CCD that allows complex formation (Figure 3).
5. Beclin 1 Phosphorylation by Receptor Tyrosine Kinases

5.1. EGFR

Epidermal growth factor receptor (EGFR) belongs to the class I of the ERBB receptor tyrosine kinases. Several ligands have been shown to bind EGFR, including TGFA (transforming growth factor-alpha), heparin-binding EGF-like growth factor (HBEGF) and betacellulin (BTC), although EGF is the most studied of all. Upon binding to its ligand, EGFR homo or heterodimerize with other family members (including HER2, HER3, HER4), leading to autophosphorylation and further recruitment of other partner proteins for intracellular signal transduction, activating the Ras/MAPK pathway, PI3K/Akt pathway, and STAT pathway. EGFR signaling is aberrantly activated in a number of cancers, including lung, head and neck, colon, brain, and pancreas, due to activating mutations, amplifications, or increased protein levels [47–50].

EGFR was shown to be an autophagy modulator through regulation of Beclin 1 tyrosine phosphorylation. Previous studies had shown that EGFR inhibitors treatment induced autophagy in multiple cancer cell lines [51,52], but the specific mechanism underlying this process was unknown. Wei and colleagues [39] showed that activated EGFR upon ligand binding promote Beclin 1-EGFR interaction at the endosomes and further Beclin 1 phosphorylation at tyrosine residues 229, 233, and Y352. These phosphorylation events promote the formation of Beclin 1 homodimers, since phosphorylated Y229/Y233 stabilize the Beclin 1 CCD homodimer, losing the ATG14 or UVRAG CCD interaction and therefore blocking the binding of the VPS34 kinase (Figure 3). Thus, tyrosine phosphorylation by EGFR releases Beclin 1 interaction with ‘activating’ binding partners such as UVRAG, VPS34,
ATG14, or VPS15 and promotes Beclin 1 homodimerization and binding to inhibitory proteins such as Bcl-2 and Rubicon, leading to autophagy inhibition. Interestingly, this effect is independent of the mTORC1 (mammalian target of rapamycin complex 1) activity, a well-known regulator of autophagy activity and a downstream target of EGFR. The importance of EGFR-phosphorylated Beclin 1 in tumorigenesis is highlighted by xenograft experiments, where NSCLC (non-small cell lung cancer) cells expressing a constitutively phosphorylated Beclin 1 mutant inhibit autophagy and enhance tumor growth and proliferation [39]. Interestingly, treatment with the receptor tyrosine kinase inhibitor Erlotinib abolished EGFR and Beclin 1 phosphorylation, disrupted EGFR/Beclin 1 binding and induced autophagy (Figure 4).

Figure 4. Models on RTK-Beclin 1 complex effects and autophagy induction upon receptor tyrosine kinase inhibitor or Tat-Beclin 1 autophagy-inducing peptide treatment.

A role of inactive EGFR on regulating autophagy to promote cell survival under serum starvation or stress conditions was also described. Inactive EGFR binds to LAPTM4B (lysosomal protein transmembrane 4b) and Sec5 (EXOC2, exocyst complex component 2) and competes with Beclin 1 for its binding with Rubicon, activating autophagy [53].

5.2. HER2

HER2 (ERBB2, v-erb-b2 avian erythroblastic leukemia viral oncogene homologue 2) is an oncogenic receptor tyrosine kinase of the EGFR family. It is amplified in around 20–25% of breast cancers and other cancer entities—such as esophagus, bladder, and cervical cancer [54,55]—and such amplification correlates with poorer prognosis. HER2 somatic mutations are also found in several cancers—such as breast, small bowel, lung, cervical, bladder, and non-melanoma tumors—mostly in tumors with no HER2 gene amplification. Such mutations are mostly missense mutations found either within the tyrosine kinase and the extracellular domains or insertions in exon 20 [54]. HER2 is an orphan receptor, and amplifications lead to increased protein production and activation through homo- and hetero-dimerization with other family members, and preferentially with HER3 and HER4 [56,57]. Upon activation, it initiates multiple intracellular cascade pathways, like the mitogenic-activated protein kinase (MAPK), RAS/MEK/ERK, PI3K and STAT, promoting cell proliferation and survival. Current
treatments for HER2+ breast cancer include receptor tyrosine kinase inhibitors (Lapatinib and Afatinib, that target both EGFR and HER2; Neratinib, that only binds to HER2), which block intracellular kinase activity, antibodies targeting the extracellular domain and inhibiting HER2 dimerization (Trastuzumab, Pertuzumab) or antibodies combined with a microtubule de-polymerization agent (Trastuzumab Emtansine; T-DM1). An antibody against p95HER2, an active C-terminal fragment of HER2, found in 40% of HER2 positive tumors have also been investigated as a potential therapy for this subset of patients [58].

Some studies suggested an association between Beclin 1 and HER2 in breast cancer, and a correlation between HER2 amplification in breast cancer with BECN1 DNA copy loss was found [59]. Furthermore, low BECN1 mRNA expression was associated with HER2 amplification [60] and a much poorer disease-specific survival in HER2+ breast cancer [21]. In vitro analysis of breast cancer cells overexpressing HER2 compared to other HER2- cell lines also suggested an inhibitory effect of HER2 on autophagy [60,61]. These data indicate a potential role of autophagy in HER2+ breast tumorigenesis, although the specific relationship between autophagy, and particularly Beclin 1 and HER2 was not addressed. Later on, it was discovered that HER2 binds to Beclin 1 in HER2+ tumor cells [40,62] and inhibits autophagy. Although such binding and the corresponding effects on autophagy inhibition are dependent on HER2 kinase activity (a kinase dead mutant D845A does not bind to Beclin 1 and fails to inhibit autophagy), despite its binding, wild-type overexpressed HER2 does not appear to phosphorylate Beclin 1 at least at levels detectable by conventional techniques. The mechanism underlying this effect is unclear, but treatment of HER2+ breast cancer cell lines with the tyrosine kinase inhibitor Lapatinib disrupts the HER2-Beclin 1 complex and induces autophagy [40,62]. Overexpression of an activated HER2 mutant (A775_G776insYVMA), however, phosphorylate Beclin 1 at Y233, also leading to autophagy inhibition. Thus, even though several HER2 forms bind to Beclin 1, wild-type HER2 does not modulate autophagy through direct Beclin 1 phosphorylation, but rather through a different, currently unclear, mechanism. Studies related to Alzheimer’s disease suggest that in this setting HER2 binding to Beclin 1 might compete with the recruitment of other proteins, including VPS34 and VPS15, therefore inhibiting autophagy [63]. However, the full details underlying this mechanism remain elusive. Thus, HER2 inhibits autophagy at least through two different mechanisms: (1) Overexpressed wild-type HER2 binds to Beclin 1 and inhibits autophagy in an mTORC1-dependent and Beclin 1-tyrosine phosphorylation independent manner; (2) Activating HER2 mutants phosphorylate Beclin 1 at Y233, promoting Beclin 1 homodimerization and inhibition of autophagy in an mTORC1-independent manner (Figure 3).

HER2+ breast cancer cells as well as xenografts derived from them are able to induce autophagy upon Lapatinib treatment, and this correlates with inhibition of HER2 phosphorylation, disruption of the HER/Beclin 1 complex and induction of autophagy. These effects might be due, at least in part, to the inhibition of other HER2/EGFR downstream pathways, and more targeted and specific treatments with an autophagy inducing peptide were tested. Tat-Beclin 1 peptide promotes autophagy through releasing Beclin 1 from its inhibitory partner GAPRA1 [64] and therefore requires Beclin 1 and downstream autophagy machinery to induce autophagy. It contains 11 amino acids from the evolutionarily conserved region of Beclin 1 [65] and it induces autophagy in vitro in multiple cell lines. It is well tolerated and also induces autophagy in vivo where has been shown to protect from infection [64,66], cardiac disease [67,68], bone disease [69], and axonal injury [70]. Tat-Beclin 1 treatment compromised the growth of xenografts derived from HER2+ breast cell lines at a similar extent as Lapatinib treatment [40]. Furthermore, it disrupted the Beclin 1/HER2 complex, activated autophagy without changes in the HER2 phosphorylation status and induced a transcriptional signature different from the one in Lapatinib-treated tumors (Figure 4). Taken together, these data indicate that autophagy plays a major role in regulating HER2+ tumor growth. HER2 overexpression found in other cancers, like esophageal adenocarcinoma, was shown to also have an inhibitory effect on autophagy, and treatment with the dual EGFR/HER2 inhibitor Lapatinib also induced autophagic flux in vitro [71].
It was demonstrated that autophagy is also essential for tumor development in HER2+ breast cancer. Transgenic mice overexpressing HER2 under the control of an MMTV mammary-specific promoter (FVB/N-Tg MMTVneu) were crossed with mice harboring a whole-body knock-in mutation (Becn1F121A/F121A) that releases the Bcl-2 inhibitory effect on Beclin 1 [72] and therefore show increased basal autophagy activity in multiple tissues, including the mammary gland. None of the Becn1F121A/F121A mice developed tumors by 450 days of life, whereas around 25% of the Becn1WT/WT mice harboring whole-body knock-in mutations developed mammary tumors [40]. These data demonstrate that bypassing the HER2 effects on Beclin 1 and autophagy by increasing basal autophagy blocks HER2-mediated tumorigenesis in vivo. Although Becn1+/− mice show an increased susceptibility to tumor formation and an elevated incidence of multiple malignancies [23,24] crossings of Becn1+/− mice with mouse models of Erbb2- or PyMT-driven mammary tumorigenesis had no effect on tumor development ([60]; Vega-Rubín-de-Celis, unpublished data).

6. Beclin 1 Phosphorylation by Non-Receptor Tyrosine Kinases

BCR-ABL

Fusion kinase BCR-ABL results from a fusion between the Breakpoint cluster region (BCR) on chromosome 22 and the Abelson murine leukemia viral oncogene homolog 1 (ABL) located in chromosome 9 [73]. It is found in ~90% of patients with chronic myeloid leukemia (CML) and ~20–30% of patients of acute lymphoblastic leukemia (ALL) and encodes for the so called “Philadelphia chromosome” (Ph). BCR-ABL forms homodimers through the BCR coiled-coil domain, rendering the ABL kinase constitutively active, and further activating several downstream pathways implicated in cell growth and proliferation, including the MAPK, CRKL, GRB2/GAB2, PI3K/Akt, and JAK/STAT pathways [74,75]. Over the years, several BCR-ABL inhibitors have reached the clinic for treatment, including Imatinib and Nilotinib (ATP-binding competitors; [76,77]), Dasatinib and Bosutinib (dual SRC/ABL1 inhibitors; [78,79]) or Asciminib (ABL1 allosteric inhibitor; [80]).

Some reports implicated autophagy as a potential target in Ph+ leukemias [81–87], and a recent paper highlighted the role of Beclin 1 phosphorylation in autophagy regulation by BCR-ABL [88]. In vitro experiments of Beclin 1 depletion through miRNA in Ba/F3 cells indicated a role of Beclin 1 in cell proliferation and apoptosis, and in vivo transplantation analysis showed a prolonged survival on Beclin 1 knock-down BCR-ABL+ BMDC compared to control samples [88]. Interestingly, these effects might be autophagy-independent, since similar experiments depleting another autophagy essential gene, Atg5, had no effect on survival. Further research into the mechanism underlying the role of Beclin 1 in leukemia lead to the finding that BCR-ABL binds to Beclin 1 and phosphorylates it at Y233 and Y352. These phosphorylation events lead to autophagy inhibition. Nilotinib treatment compromised the Beclin 1/BCR-ABL binding (Figure 3), and induced autophagy in a way that is dependent on Beclin 1 tyrosine phosphorylation, since Beclin 1 phosphomimetic mutant Y233/352E fail to induce autophagy upon RTK inhibitor treatment. The specific function of these Beclin 1 tyrosine residues in vivo and whether the effects on survival are autophagy-dependent remain to be determined.

7. Other Tyrosine Kinases Regulating Autophagy

Other oncogenic tyrosine kinases have been involved in regulating autophagy, especially since treatments with tyrosine kinase inhibitors in many cases induce autophagy. However, it is still unclear whether these processes involve Beclin 1 tyrosine phosphorylation or there are other mechanisms implicated. For instance, Rearranged during transfection (RET), a Class XIV Receptor Tyrosine Kinase is associated with multiple malignancies through different mechanisms, including activating mutations and gene fusions [89–95], and it was recently identified in a shRNA screen as an essential gene in AML that activates mTORC1 and therefore inhibits autophagy [96]. Conversely, RET knockdown induced autophagy and a correlation between high RET and high p62 levels was found in patients [96]. The role of amplified fibroblast growth factor receptor 1 (FGFR1) in autophagy in NSCLC was also
explored in a recent study where it was reported that FGFR1 activation by its ligand inhibit autophagy through the ERK-MAPK pathway and regulation of the total Beclin 1 levels [97]. A recent report [98] described discoidin domain receptor 1 (DDR1) as an autophagy regulator in glioblastoma resistance to radiochemotherapy through its binding to the 14-3-3/Akt/Beclin 1 complex [38]. DDR1 inhibition induces autophagy and sensitizes cells to radiation in a way that is Beclin 1-dependent. Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase of the Class XVI that has been found to be implicated in multiple cancers through aberrant activation due to point mutations, overexpression, or a diversity of translocations giving rise to fusion proteins [99]. Studies in ALK+ anaplastic large cell lymphoma showed that treatment with the tyrosine kinase inhibitor crizotinib induced autophagy and that combination of ALK inhibition with Bcl-2 depletion induced autophagy and cell death [100,101], and autophagy induction was also found upon ALK inhibition in glioblastoma [102]. Aberrant RTK signaling is also involved in hepatocellular carcinoma (HCC), and RTK inhibitor sorafenib is used for therapy and was shown to induce autophagy in multiple systems [103].

8. Conclusions

Autophagy is regulated by tyrosine kinases directly or indirectly in multiple ways, through mechanisms largely unexplored. Some of them involve the phosphorylation of Beclin 1 at different tyrosine residues that ultimately regulate the activity of the PI3KC3 and affect tumor growth. Further and deeper studies are required to delineate the fine-tuned mechanism in each particular context and tumor type.

Author Contributions: S.V.-R.-d.-C. and L.K. wrote the manuscript. S.V.-R.-d.-C., L.K., and S.P.-L. generated figures, and revised and edited the paper. All authors have read and agreed to the published version of the manuscript.

Funding: Silvia Vega-Rubin-de-Celis is supported by a Deutsche Forschungsgemeinschaft (DFG) grant (VE-1153/1-1).

Acknowledgments: This paper is dedicated to the memory of Beth Levine, wonderful mentor and amazing person, role model for so many and a real pioneer on the autophagy field. We acknowledge support by the Open Access Publication Fund of the University of Duisburg-Essen.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Beau, I.; Mehrpour, M.; Codogno, P. Autophagosomes and human diseases. Int. J. Biochem. Cell Biol. 2011, 43, 460–464. [CrossRef]
2. Levine, B.; Kroemer, G. Autophagy in the pathogenesis of disease. Cell 2008, 132, 27–42. [CrossRef]
3. Mizushima, N.; Levine, B.; Cuervo, A.M.; Klionsky, D.J. Autophagy fights disease through cellular self-digestion. Nature 2008, 451, 1069–1075. [CrossRef]
4. Sarkar, S. Chemical screening platforms for autophagy drug discovery to identify therapeutic candidates for Huntington’s disease and other neurodegenerative disorders. Drug Discov. Today Technol. 2013, 10, e137–e144. [CrossRef] [PubMed]
5. Schneider, J.L.; Cuervo, A.M. Autophagy and human disease: Emerging themes. Curr. Opin. Genet. Dev. 2014, 26, 16–23. [CrossRef] [PubMed]
6. Levine, B.; Kroemer, G. Biological Functions of Autophagy Genes: A Disease Perspective. Cell 2019, 176, 11–42. [CrossRef] [PubMed]
7. Liang, X.H.; Kleeman, L.K.; Jiang, H.H.; Gordon, G.; Goldman, J.E.; Berry, G.; Herman, B.; Levine, B. Protection against fatal Sindbis virus encephalitis by beclin, a novel Bcl-2-interacting protein. J. Virol. 1998, 72, 8586–8596. [CrossRef] [PubMed]
8. Pattingre, S.; Tassa, A.; Qu, X.; Garuti, R.; Liang, X.H.; Mizushima, N.; Packer, M.; Schneider, M.D.; Levine, B. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 2005, 122, 927–939. [CrossRef] [PubMed]
9. Matsunaga, K.; Saitoh, T.; Tabata, K.; Omori, H.; Sato, T.; Kurotori, M.; Majeima, I.; Shirahama-Noda, K.; Ichimura, T.; Isober, T.; et al. Two Beclin 1-binding proteins, Atg14L and Rubicon, reciprocally regulate autophagy at different stages. Nat. Cell Biol. 2009, 11, 385–396. [CrossRef]

10. Sun, Q.; Zhang, J.; Fan, W.; Kong, K.N.; Ding, X.; Chen, S.; Zhong, Q. The RUN domain of rubicon is important for hVps34 binding, lipid kinase inhibition, and autophagy suppression. J. Biol. Chem. 2011, 286, 185–191. [CrossRef]

11. Zhong, Y.; Wang, Q.J.; Li, X.; Yan, Y.; Backer, J.M.; Chait, B.T.; Heintz, N.; Yue, Z. Distinct regulation of autophagic activity by Atg14L and Rubicon associated with Beclin 1-phosphatidylinositol-3-kinase complex. Nat. Cell Biol. 2009, 11, 468–476. [CrossRef] [PubMed]

12. Wei, Y.; Pattingre, S.; Sinha, S.; Bassik, M.; Levine, B. JNK1-mediated phosphorylation of Bcl-2 regulates starvation-induced autophagy. Mol. Cell 2008, 30, 678–688. [CrossRef] [PubMed]

13. Gurkar, A.U.; Chu, K.; Raj, L.; Bouley, R.; Lee, S.H.; Kim, Y.B.; Dunn, S.E.; Mandinova, A.; Lee, S.W. Identification of ROCK1 kinase as a critical regulator of Beclin1-mediated autophagy during metabolic stress. Nat. Commun. 2013, 4, 2189. [CrossRef] [PubMed]

14. Zalckvar, E.; Berissi, H.; Mizrahy, L.; Idelchuk, Y.; Koren, I.; Eisenstein, M.; Sabanay, H.; Pinkas-Kramarski, R.; Kimchi, A. DAP-kinase-mediated phosphorylation on the BH3 domain of beclin 1 promotes dissociation of beclin 1 from Bcl-XL and induction of autophagy. EMBO Rep. 2009, 10, 285–292. [CrossRef] [PubMed]

15. Wei, Y.; An, Z.; Zou, Z.; Sumpter, R.; Su, M.; Zhang, X.; Sinha, S.; Gaestel, M.; Levine, B. The stress-responsive kinases MAPKAPK2/MAPKAPK3 activate starvation-induced autophagy through Beclin 1 phosphorylation. eLife 2015, 4. [CrossRef] [PubMed]

16. Maejima, Y.; Kyoi, S.; Zhai, P.; Liu, T.; Li, H.; Ivessa, A.; Scarretta, S.; Del Re, D.P.; Zablocki, D.K.; Hsu, C.P.; et al. Mst1 inhibits autophagy by promoting the interaction between Beclin1 and Bcl-2. Nat. Med. 2013, 19, 1478–1488. [CrossRef]

17. Aita, V.M.; Liang, X.H.; Murty, V.V.; Pincus, D.L.; Yu, W.; Cayamis, E.; Kalachikov, S.; Gilliam, T.C.; Levine, B. Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21. Genomics 1999, 59, 59–65. [CrossRef] [PubMed]

18. Li, Z.; Chen, B.; Wu, Y.; Jin, F.; Xia, Y.; Liu, X. Genetic and epigenetic silencing of the beclin 1 gene in sporadic breast tumors. BMC Cancer 2010, 10, 98. [CrossRef]

19. Liang, X.H.; Jackson, S.; Seaman, M.; Brown, K.; Kempkes, B.; Hibschoosh, H.; Levine, B. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 1999, 402, 672–676. [CrossRef]

20. Valente, G.; Morani, F.; Nicotra, G.; Fusco, N.; Peracchio, C.; Titone, R.; Alabiso, O.; Arisio, R.; Katsaras, D.; Benedetto, C.; et al. Expression and clinical significance of the autophagy proteins BECLIN 1 and LC3 in ovarian cancer. BioMed Res. Int. 2014, 2014, 462658. [CrossRef]

21. Tang, H.; Sebti, S.; Titone, R.; Zhou, Y.; Isidoro, C.; Ross, T.S.; Hibshoosh, H.; Xiao, G.; Packer, M.; Xie, Y.; et al. Decreased mRNA Expression in Human Breast Cancer is Associated with Estrogen Receptor-Negative Subtypes and Poor Prognosis. EBioMedicine 2015, 2, 255–263. [CrossRef] [PubMed]

22. Cicchini, M.; Chakrabarti, R.; Kongara, S.; Price, S.; Nahar, R.; Lozy, F.; Zhong, H.; Vazquez, A.; Kang, Y.; Karantza, V. Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parathyroidism. Autophagy 2014, 10, 2036–2052. [CrossRef] [PubMed]

23. Qu, X.; Yu, J.; Bhagat, G.; Furuya, N.; Hibshoosh, H.; Troxel, A.; Rosen, J.; Eskelinen, E.L.; Mizushima, N.; Ohsumi, Y.; et al. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J. Clin. Investig. 2003, 112, 1809–1820. [CrossRef] [PubMed]

24. Yue, Z.; Jin, S.; Yang, C.; Levine, A.J.; Heintz, N. Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc. Natl. Acad. Sci. USA 2003, 100, 15077–15082. [CrossRef] [PubMed]

25. Hubbard, S.R.; Till, J.H. Protein tyrosine kinase structure and function. Annu. Rev. Biochem. 2000, 69, 373–398. [CrossRef] [PubMed]

26. Lemmon, M.A.; Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 2010, 141, 1117–1134. [CrossRef] [PubMed]

27. Du, Z.; Lovly, C.M. Mechanisms of receptor tyrosine kinase activation in cancer. Mol. Cancer 2018, 17, 58. [CrossRef]

28. Schenk, P.W.; Snaar-Jagalska, B.E. Signal perception and transduction: The role of protein kinases. Biochim. Biophys. Acta 1999, 1449, 1–24. [CrossRef]
29. Siveen, K.S.; Prabhu, K.S.; Achkar, I.W.; Kuttikrishnan, S.; Shyam, S.; Khan, A.Q.; Merhi, M.; Dermime, S.; Uddin, S. Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products. *Mol. Cancer* 2018, 17, 31. [CrossRef]

30. Hill, S.M.; Wrobel, L.; Rubinsztein, D.C. Post-translational modifications of Beclin 1 provide multiple strategies for autophagy regulation. *Cell Death Differ.* 2019, 26, 617–629. [CrossRef] [PubMed]

31. Hill, S.M.; Wrobel, L.; Rubinsztein, D.C. Post-translational modifications of Beclin 1 provide multiple strategies for autophagy regulation. *Cell Death Differ.* 2019, 26, 617–629. [CrossRef] [PubMed]

32. Vega-Rubin-de-Celis, S. The Role of Beclin 1-Dependent Autophagy in Cancer. *Biology* 2019, 9, 4. [CrossRef] [PubMed]

33. Fujiwara, N.; Usui, T.; Ohama, T.; Sato, K. Regulation of Beclin 1 Protein Phosphorylation and Autophagy by Protein Phosphatase 2A (PP2A) and Death-associated Protein Kinase 3 (DAPK3). *J. Biol. Chem.* 2016, 291, 10858–10866. [CrossRef] [PubMed]

34. Li, X.; Wu, X.Q.; Deng, R.; Li, D.D.; Tang, J.; Chen, W.D.; Chen, J.H.; Ji, J.; Jiao, L.; Jiang, S.; et al. CaMKII-mediated Beclin 1 phosphorylation regulates autophagy that promotes degradation of Id and neuroblastoma cell differentiation. *Nat. Commun.* 2017, 8, 1159. [CrossRef]

35. Li, X.; Wu, X.Q.; Deng, R.; Li, D.D.; Tang, J.; Chen, W.D.; Chen, J.H.; Ji, J.; Jiao, L.; Jiang, S.; et al. CaMKII-mediated Beclin 1 phosphorylation regulates autophagy that promotes degradation of Id and neuroblastoma cell differentiation. *Nat. Commun.* 2017, 8, 1159. [CrossRef]

36. Zhang, D.; Wang, W.; Sun, X.; Yu, D.; Wang, C.; Zhang, Q.; Wang, H.; Luo, W.; Chen, Y.; Chen, H.; et al. AMPK regulates autophagy by phosphorylating BECN1 at threonine 388. *Autophagy* 2016, 12, 1447–1459. [CrossRef]

37. Qian, X.; Li, X.; Cai, Q.; Zhang, C.; Yu, Q.; Jiang, Y.; Lee, J.H.; Hawke, D.; Wang, Y.; Xia, Y.; et al. Phosphoglycerate Kinase 1 Phosphorylates Beclin1 to Induce Autophagy. *Mol. Cell* 2017, 65, 917–931.e916. [CrossRef]

38. Wang, R.C.; Wei, Y.; An, Z.; Zou, Z.; Xiao, G.; Bhagat, G.; White, M.; Reichelt, J.; Levine, B. Akt-mediated regulation of autophagy and tumorigenesis through Beclin 1 phosphorylation. *Science* 2012, 338, 956–959. [CrossRef]

39. Wei, Y.; Zou, Z.; Becker, N.; Anderson, M.; Sumpter, R.; Xiao, G.; Kinch, L.; Koduru, P.; Christudass, C.S.; Veltre, R.W.; et al. EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance. *Cell* 2013, 154, 1269–1284. [CrossRef]

40. Vega-Rubin-de-Celis, S.; Zou, Z.; Fernandez, A.F.; Ci, B.; Kim, M.; Xiao, G.; Xie, Y.; Levine, B. Increased autophagy blocks HER2-mediated breast tumorigenesis. *Proc. Natl. Acad. Sci. USA* 2018, 115, 4176–4181. [CrossRef]

41. Cheng, Z.; Zhu, Q.; Dee, R.; Opheim, Z.; Mack, C.P.; Cyr, D.M.; Taylor, J.M. Focal Adhesion Kinase-mediated Phosphorylation of Beclin1 Protein Suppresses Cardiomyocyte Autophagy and Initiates Hypertrophic Growth. *J. Biol. Chem.* 2017, 292, 2065–2079. [CrossRef]

42. Rostislavleva, K.; Soler, N.; Ohashi, Y.; Zhang, L.; Pardon, E.; Burke, J.E.; Masson, G.R.; Johnson, C.; Steyaert, J.; Ktistakis, N.T.; et al. Structure and flexibility of the endosomal Vps34 complex reveals the basis of its function on membranes. *Science* 2015, 350, aac7365. [CrossRef] [PubMed]

43. Huang, W.; Choi, W.; Hu, W.; Mi, N.; Guo, Q.; Ma, M.; Liu, M.; Tian, Y.; Lu, P.; Wang, F.L.; et al. Crystal structure and biochemical analyses reveal Beclin 1 as a novel membrane binding protein. *Cell Res.* 2012, 22, 473–489. [CrossRef] [PubMed]

44. Li, X.; He, L.; Che, K.H.; Funderburk, S.F.; Pan, L.; Pan, N.; Zhang, M.; Yue, Z.; Zhao, Y. Imperfect interface of Beclin1 coiled-coil domain regulates homodimer and heterodimer formation with Atg14L and UVRAG. *Nat. Commun.* 2012, 3, 662. [CrossRef] [PubMed]

45. Mei, Y.; Su, M.; Sanishvili, R.; Chakravarthy, S.; Colbert, C.L.; Sinha, S.C. Identification of BECN1 and ATG14 Coiled-Coil Interface Residues That Are Important for Starvation-Induced Autophagy. *Biochemistry* 2016, 55, 4239–4253. [CrossRef] [PubMed]

46. Ranaghan, M.J.; Durney, M.A.; Mesleh, M.F.; McCarron, P.R.; Garvie, C.W.; Daniels, D.S.; Carey, K.L.; Skepner, A.P.; Levine, B.; Perez, J.R. The Autophagy-Related Beclin-1 Protein Requires the Coiled-Coil and BARA Domains To Form a Homodimer with Submicromolar Affinity. *Biochemistry* 2017, 56, 6639–6651. [CrossRef] [PubMed]
47. Lynch, T.J.; Bell, D.W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R.A.; Brannigan, B.W.; Harris, P.L.; Haserlat, S.M.; Supko, J.G.; Haluska, F.G.; et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N. Engl. J. Med.* 2004, 350, 2129–2139. [CrossRef] [PubMed]

48. Paez, J.G.; Janne, P.A.; Lee, J.C.; Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, F.J.; Lindeman, N.; Boggon, T.J.; et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. *Science* 2004, 304, 1497–1500. [CrossRef]

49. Sugawa, N.; Ekstrand, A.J.; James, C.D.; Collins, V.P. Identical Splicing of Aberrant Epidermal Growth Factor Receptor Transcripts from Amplified Rearranged Genes in Human Glioblastomas. *Proc. Natl. Acad. Sci. USA* 1990, 87, 8602–8606. [CrossRef]

50. Yarden, Y.; Pines, G. The ERBB network: At last, cancer therapy meets systems biology. *Nat. Rev. Cancer* 2012, 12, 553–563. [CrossRef]

51. Fung, C.; Chen, X.; Grandis, J.R.; Duvvuri, U. EGFR tyrosine kinase inhibition induces autophagy in cancer cells. *Cancer Biol. Ther* 2012, 13, 1417–1424. [CrossRef] [PubMed]

52. Han, W.; Pan, H.; Chen, Y.; Sun, J.; Wang, Y.; Li, J.; Ge, W.; Feng, L.; Lin, X.; Wang, X.; et al. EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells. *PLoS ONE* 2011, 6, e18691. [CrossRef] [PubMed]

53. Tan, X.; Thapa, N.; Sun, Y.; Anderson, R.A. A kinase-independent role for EGF receptor in autophagy initiation. *Cell* 2015, 160, 145–160. [CrossRef] [PubMed]

54. Cancer Genome Atlas, N. Comprehensive molecular portraits of human breast tumours. *Nature* 2012, 490, 61–70. [CrossRef] [PubMed]

55. Yan, M.; Schwaederle, M.; Arguello, D.; Millis, S.Z.; Gatalica, Z.; Kurzrock, R. HER2 expression status in diverse cancers: Review of results from 37,992 patients. *Cancer Metastasis Rev.* 2015, 34, 157–164. [CrossRef] [PubMed]

56. Cho, H.S.; Mason, K.; Ramyar, K.X.; Stanley, A.M.; Gabelli, S.B.; Denney, D.W., Jr.; Leahy, D.J. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. *Nature* 2003, 421, 756–760. [CrossRef]

57. Garrett, T.P.; McKern, N.M.; Lou, M.; Elleman, T.C.; Adams, T.E.; Lovrecz, G.O.; Kofler, M.; Jorissen, R.N.; Nice, E.C.; Burgess, A.W.; et al. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. *Mol. Cell* 2003, 11, 495–505. [CrossRef]

58. Rius Ruiz, I.; Vicario, R.; Morencho, B.; Morales, C.B.; Arenas, E.J.; Herter, S.; Freimoser-Grundschober, A.; Somandin, J.; Sam, J.; Ast, O.; et al. p95HER2-T cell bispecific antibody for breast cancer treatment. *Sci. Transl. Med.* 2018, 10. [CrossRef]

59. Negri, T.; Tarantino, E.; Orsenigo, M.; Reid, J.F.; Gariboldi, M.; Zambetti, M.; Pierotti, M.A.; Pilotti, S. Chromosome band 17q21 in breast cancer: Significant association between beclin 1 loss and HER2/NEU amplification. *Genes Chromosom. Cancer* 2010, 49, 901–909. [CrossRef]

60. Lozy, F.; Cai-McRae, X.; Teplova, I.; Price, S.; Reddy, A.; Bhanot, G.; Ganesan, S.; Vazquez, A.; Karantzas, V. ERBB2 overexpression suppresses stress-induced autophagy and renders ERBB2-induced mammary tumorigenesis independent of monoallelic Becn1 loss. *Autophagy* 2014, 10, 662–676. [CrossRef]

61. Lefort, S.; Joffre, C.; Kieffer, Y.; Givel, A.M.; Bourachot, B.; Zago, G.; Bieche, I.; Dubois, T.; Meseure, D.; Vincent-Salomon, A.; et al. Inhibition of autophagy as a new means of improving chemotherapy efficiency in high-LC3B triple-negative breast cancers. *Autophagy* 2014, 10, 2122–2142. [CrossRef] [PubMed]

62. Han, J.; Hou, W.; Lu, C.; Goldstein, L.A.; Stolz, D.B.; Watkins, S.C.; Rabinowich, H. Interaction between Her2 and Beclin-1 proteins underlies a new mechanism of reciprocal regulation. *J. Biol. Chem.* 2013, 288, 20315–20325. [CrossRef] [PubMed]

63. Wang, B.J.; Her, G.M.; Hu, M.K.; Chen, Y.W.; Tung, Y.T.; Wu, P.Y.; Hsu, W.M.; Lee, H.; Jin, L.W.; Hwang, S.L.; et al. ErbB2 regulates autophagic flux to modulate the proteostasis of APP-CTFs in Alzheimer’s disease. *Proc. Natl. Acad. Sci. USA* 2017, 114, E3129–E3138. [CrossRef] [PubMed]

64. Shoji-Kawata, S.; Sumpter, R.; Leveno, M.; Campbell, G.R.; Zou, Z.; Kinch, L.; Wilkins, A.D.; Sun, Q.; Pallau, K.; MacDuff, D.; et al. Identification of a candidate therapeutic autophagy-inducing peptide. *Nature* 2013, 494, 201–206. [CrossRef] [PubMed]
65. Peraro, L.; Zou, Z.; Makwana, K.M.; Cummings, A.E.; Ball, H.L.; Yu, H.; Lin, Y.S.; Levine, B.; Kritzer, J.A. Diversity-Oriented Stapling Yields Intrinsically Cell-Penetrant Inducers of Autophagy. *J. Am. Chem. Soc.* 2017, 139, 7792–7802. [CrossRef]

66. Miao, Y.; Li, G.; Zhang, X.; Xu, H.; Abraham, S.N. A TRP Channel Senses Lysosome Neutralization by Pathogens to Trigger Their Expulsion. *Cell* 2015, 161, 1306–1319. [CrossRef]

67. Shirakabe, A.; Zhai, P.; Ikeda, Y.; Saito, T.; Maejima, Y.; Hsu, C.P.; Nomura, M.; Egashira, K.; Levine, B.; Sadoshima, J. Drp1-Dependent Mitochondrial Autophagy Plays a Protective Role Against Pressure Overload-Induced Mitochondrial Dysfunction and Heart Failure. *Circulation* 2016, 133, 1249–1263. [CrossRef]

68. An, M.; Ryu, D.R.; Won Park, J.; Ha Choi, J.; Park, E.M.; Eun Lee, K.; Woo, M.; Kim, M. ULK1 prevents cardiac dysfunction in obesity through autophagy-mediated regulation of lipid metabolism. *Cardiovasc. Res.* 2017. [CrossRef]

69. Cinque, L.; Forrester, A.; Bartolomeo, R.; Svelto, M.; Venditti, R.; Montefusco, S.; Polishchuk, E.; Nusco, E.; Rossi, A.; Medina, D.L.; et al. FGF signalling regulates bone growth through autophagy. *Nature* 2015, 528, 272–275. [CrossRef]

70. He, M.; Ding, Y.; Chu, C.; Tang, J.; Xiao, Q.; Luo, Z.G. Autophagy induction stabilizes microtubules and promotes axon regeneration after spinal cord injury. *Proc. Natl. Acad. Sci. USA* 2016, 113, 11324–11329. [CrossRef]

71. Janser, F.A.; Adams, O.; Butler, V.; Schlafli, A.M.; Dislich, B.; Seiler, C.A.; Kroll, D.; Langer, R.; Tschan, M.P. Her2-Targeted Therapy Induces Autophagy in Esophageal Adenocarcinoma Cells. *Int. J. Mol. Sci.* 2018, 19, 69. [CrossRef] [PubMed]

72. Fernandez, A.F.; Sebti, S.; Wei, Y.; Zou, Z.; Shi, M.; McMillan, K.L.; He, C.; Ting, T.; Liu, Y.; Chiang, W.C.; et al. Disruption of the beclin 1-BCL2 autophagy regulatory complex promotes longevity in mice. *Nature* 2018, 558, 136–140. [CrossRef] [PubMed]

73. Groffen, J.; Stephenson, J.R.; Heisterkamp, N.; de Klein, A.; Bartram, C.R.; Grosveld, G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. *Cell* 1984, 36, 93–99. [CrossRef]

74. Brehme, M.; Hantschel, O.; Colinge, J.; Kaupe, I.; Planyavsky, M.; Kocher, T.; Mechtler, K.; Bennett, K.L.; Superti-Furga, G. Charting the molecular network of the drug target Bcr-Abl. *Proc. Natl. Acad. Sci. USA* 2009, 106, 7414–7419. [CrossRef]

75. Goss, V.L.; Lee, K.A.; Moritz, A.; Nardone, J.; Spek, E.J.; MacNeill, J.; Rush, J.; Comb, M.J.; Polakiewicz, R.D. A common phosphotyrosine signature for the Bcr-Abl kinase. *Blood* 2006, 107, 4888–4897. [CrossRef]

76. Druker, B.J.; Tamura, S.; Buchdunger, E.; Ohno, S.; Segal, G.M.; Fanning, S.; Zimmermann, J.; Lydon, N.B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. *Nat. Med.* 1996, 2, 561–566. [CrossRef]

77. Weisberg, E.; Manley, P.W.; Breitenstein, W.; Bruggen, J.; Cowan-Jacob, S.W.; Ray, A.; Huntly, B.; Fabbro, D.; Hendrich, G.; Hall-Meyers, E.; et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. *Cancer Cell* 2005, 7, 129–141. [CrossRef]

78. Golas, J.M.; Arndt, K.; Etienne, C.; Lucas, J.; Nardin, D.; Gibbons, J.; Frost, P.; Ye, F.; Boschelli, D.H.; Boschelli, F. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. *Cancer Res.* 2003, 63, 375–381.

79. Shah, N.P.; Tran, C.; Lee, F.Y.; Chen, P.; Norris, D.; Sawyers, C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. *Science* 2004, 305, 399–401. [CrossRef]

80. Wylie, A.A.; Schoepfer, J.; Jahnke, W.; Cowan-Jacob, S.W.; Ray, A.; Huntly, B.; Fabbro, D.; Hendrich, G.; Hall-Meyers, E.; et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. *Cancer Cell* 2005, 7, 129–141. [CrossRef]

81. Altman, B.J.; Jacobs, S.R.; Mason, E.F.; Michalek, R.D.; MacIntyre, A.N.; Coloff, J.L.; Ilkayeva, O.; Jia, W.; He, Y.W.; Rathmell, J.C. Autophagy is essential to suppress cell stress and to allow BCR-Abl-mediated leukemogenesis. *Oncogene* 2011, 30, 1855–1867. [CrossRef] [PubMed]

82. Bellodi, C.; Lidonnici, M.R.; Hamilton, A.; Helgason, G.V.; Soliera, A.R.; Ronchetti, M.; Galavotti, S.; Young, K.W.; Selmi, T.; Yacobi, R.; et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. *J. Clin. Investig.* 2009, 119, 1109–1123. [CrossRef] [PubMed]
83. Helgason, G.V.; Karvela, M.; Holyoake, T.L. Kill one bird with two stones: Potential efficacy of BCR-ABL and autophagy inhibition in CML. *Blood* 2011, 118, 2035–2043. [CrossRef] [PubMed]

84. Karvela, M.; Baquero, P.; Kunz, E.M.; Mukhopadhyay, A.; Mitchell, R.; Allan, E.K.; Chan, E.; Kranc, K.R.; Calabretta, B.; Salomoni, P.; et al. ATG7 regulates energy metabolism, differentiation and survival of Philadelphia-chromosome-positive cells. *Autophagy* 2016, 12, 936–948. [CrossRef]

85. Mitchell, R.; Hopcroft, L.E.M.; Baquero, P.; Allan, E.K.; Hewit, K.; James, D.; Hamilton, G.; Mukhopadhyay, A.; O’Prey, J.; Hair, A.; et al. Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition. *J. Natl. Cancer Inst.* 2018, 110, 467–478. [CrossRef]

86. Sheng, Z.; Ma, L.; Sun, J.E.; Zhu, L.J.; Green, M.R. BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcription. *Blood* 2011, 118, 2840–2848. [CrossRef]

87. Yu, Y.; Yang, L.; Zhao, M.; Zhu, S.; Kang, R.; Vernon, P.; Tang, D.; Cao, L. Targeting microRNA-30a-mediated autophagy enhances imatinib activity against human chronic myeloid leukemia cells. *Leukemia* 2012, 26, 1752–1760. [CrossRef]

88. Yu, C.; Gorantla, S.P.; Muller-Rudorf, A.; Muller, T.A.; Kreutmaier, S.; Albers, C.; Jakob, L.; Lippert, L.J.; Yue, Z.; Engelhardt, M.; et al. Phosphorylation of Beclin-1 by BCR-ABL suppresses autophagy in chronic myeloid leukemia. *Haematologica* 2019. [CrossRef]

89. Ballerini, P.; Struski, S.; Cresson, C.; Prade, N.; Toujani, S.; Deswarte, C.; Dobbelstein, S.; Petit, A.; Lapillonne, H.; Gautier, E.F.; et al. RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation. *Leukemia* 2012, 26, 2384–2389. [CrossRef]

90. Grieco, M.; Santoro, M.; Berlingieri, M.T.; Melillo, R.M.; Donghi, R.; Bongarzone, I.; Pierotti, M.A.; Della Porta, G.; Fusco, A.; Vecchio, G. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. *Cell* 1990, 60, 557–563. [CrossRef]

91. Hofstra, R.M.; Landsvater, R.M.; Ceccherini, I.; Stulp, R.P.; Stelwagen, T.; Luo, Y.; Pasini, B.; Hoppener, J.W.; van Amstel, H.K.; Romeo, G.; et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. *Nature* 1994, 367, 375–376. [CrossRef] [PubMed]

92. Kohno, T.; Ichikawa, H.; Totoki, Y.; Yasuda, K.; Hiramoto, M.; Nammo, T.; Sakamoto, H.; Tsuta, K.; Furuta, K.; Shimada, Y.; et al. KIF5B-RET fusions in lung adenocarcinoma. *Nat. Med.* 2012, 18, 375–377. [CrossRef]

93. Lipson, D.; Capelletti, M.; Yelensky, R.; Otto, G.; Parker, A.; Jarosz, M.; Curran, J.A.; Balasubramanian, S.; Bloom, T.; Brennan, K.W.; et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. *Nat. Med.* 2012, 18, 382–384. [CrossRef] [PubMed]

94. Mulligan, L.M.; Kwok, J.B.; Healey, C.S.; Elsdon, M.J.; Eng, C.; Gardner, E.; Love, D.R.; Mole, S.E.; Moore, J.K.; Papi, L.; et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. *Nature* 1993, 363, 456–460. [CrossRef] [PubMed]

95. Takeuchi, K.; Soda, M.; Towashi, Y.; Suzuki, R.; Sakata, S.; Hatano, S.; Asaka, R.; Hamanaka, W.; Ninomiya, H.; Uehara, H.; et al. RET, ROS1 and ALK fusions in lung cancer. *Nat. Med.* 2012, 18, 378–381. [CrossRef]

96. Rudat, S.; Pfau, A.; Cheng, Y.Y.; Holtmann, J.; Ellegast, J.M.; Buhler, C.; Marcantonio, D.D.; Martinez, E.; Gollner, S.; Wickenhauser, C.; et al. RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia. *Leukemia* 2018, 32, 2189–2202. [CrossRef]

97. Yuan, H.; Li, Z.M.; Shao, J.; Ji, W.X.; Xia, W.; Lu, S. FGFR2/FGFR1 regulates autophagy in FGFR1-amplified non-small cell lung cancer cells. *J. Exp. Clin. Cancer Res.* 2017, 36, 72. [CrossRef]

98. Vehlow, A.; Klapproth, E.; Jin, S.; Hannen, R.; Hauswald, M.; Bartsch, J.W.; Nimsky, C.; Temme, A.; Leitinger, B.; Cordes, N. Interaction of Discoidin Domain Receptor 1 with a 14-3-3-Beclin-1-Akt1 Complex Modulates Glioblastoma Therapy Sensitivity. *Cell Rep.* 2019, 2026, 2189–2202. [CrossRef]

99. Hallberg, B.; Palmer, R.H. Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. *Nat. Rev. Cancer* 2013, 13, 685–700. [CrossRef]

100. Mitou, G.; Frentzel, J.; Desquesnes, A.; Le Gonidec, S.; AlSaati, T.; Beau, I.; Lamant, L.; Meggetto, F.; Espinos, E.; Codogno, P.; et al. Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma. *Oncotarget* 2015, 6, 30149–30164. [CrossRef]

101. Torossian, A.; Broin, N.; Frentzel, J.; Daugros, C.; Gandiarillas, S.; Saati, T.A.; Lamant, L.; Brousset, P.; Giuriato, S.; Espinos, E. Blockade of crizotinib-induced BCL2 elevation in ALK-positive anaplastic large cell lymphoma triggers autophagy associated with cell death. *Haematologica* 2019, 104, 1428–1439. [CrossRef] [PubMed]
102. Lopez-Valero, I.; Davila, D.; Gonzalez-Martinez, J.; Salvador-Tormo, N.; Lorente, M.; Saiz-Ladera, C.; Torres, S.; Gabicagogeas, E.; Hernandez-Tiedra, S.; Garcia-Taboada, E.; et al. Midkine signaling maintains the self-renewal and tumorigenic capacity of glioma initiating cells. *Theranostics* **2020**, *10*, 5120–5136. [CrossRef] [PubMed]

103. Prieto-Dominguez, N.; Ordonez, R.; Fernandez, A.; Garcia-Palomo, A.; Muntane, J.; Gonzalez-Gallego, J.; Mauriz, J.L. Modulation of Autophagy by Sorafenib: Effects on Treatment Response. *Front. Pharmacol.* **2016**, *7*, 151. [CrossRef] [PubMed]

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).